Skip to content
World City Press – Lifestyle
Author:
Liminatus Pharma Inc.
Liminatus Pharma Announces Nasdaq Delisting Notification
May 21, 2026
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
May 21, 2026
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody
March 17, 2026